ArticleClinical and experimental hepatology2024
Prevalence of hepatitis C virus antibodies and associated risks among residents in long-term assisted living facilities and shelters in Latvia.
Article in Clinical and experimental hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim of the study: This was a retrospective study which aimed to analyse two-year (October 1, 2020 to October 31, 2022) data collected by HIV Prevention Point employees during their routine work and to update hepatitis C virus (HCV) prevalence among residents of long-term assisted living facilities (LTALF) and shelters in Latvia. Key objectives included investigating risk factors associated with HCV infection and analysing demographic characteristics contributing to prevalence. Material and methods: Retrospective analysis of the screening involved 46 LTALF and 6 shelters, randomly selected from Latvia's social service providers register where HCV rapid plasma immunochromatographic antibody tests were used, as well as demographic and risk-related questions asked to participants. Data were recorded, transferred to Google Sheets, and statistically analysed using SPSS software. Results: Out of 2838 tests in LTALF and 349 in shelters, HCV prevalence was 4.2% and 12.0%, respectively. Risk factors such as intravenous narcotic use, incarceration, and unprotected sex were significantly associated with HCV prevalence in both populations. Males had higher prevalence rates than females, particularly in LTALF. Conclusions: The study revealed an HCV prevalence in LTALF almost twice that of the general population and four times higher in shelters. Those denying prior incarceration or intravenous narcotic use still exhibited higher prevalence rates. Significant risk factors included intravenous narcotic use, prior incarceration and unprotected sex. The findings highlight the need for targeted interventions in these high-risk populations and emphasize the importance of tailored prevention, screening, and treatment strategies. The urgency of addressing elevated prevalence rates in LTALF and shelters is underscored, calling for immediate and targeted public health interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.